Bicycle Therapeutics Press Release

Cambridge u k and cambridge mass may 31 2018 bicycle therapeutics a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide bicycle product platform today announced the formation of a scientific advisory board sab comprised of world leading experts in oncology immunology and drug discovery and development.

Bicycle therapeutics press release. Forward looking statements in this press release include but are not limited to statements regarding statements regarding the clinical development of bt1718 or any of bicycle s other product. We didn t wait for the next advance against cancer. Press release return to press releases cambridge u k and boston mass may 7 2019 bicycle therapeutics a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide bicycle product platform today announced a collaboration with the dementia discovery fund ddf to use bicycle technology for the development of novel therapeutics for neurodegenerative diseases. Bcyc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide bicycle technology today announced that new translational research.

The trial is. See us on twitter social media bicycle tx september 2 2020 today we. Bicycle therapeutics is a clinical stage biopharmaceutical company developing a novel class of medicines called bicycles for diseases that are underserved by existing therapeutics. Cambridge u k and boston mass march 18 2019 bicycle therapeutics a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide bicycle product platform announced today the appointment of pierre legault mba cpa as a director and chairman of the board of directors.

Leone as chief business officer and the promotion of lee kalowski chief financial officer to the role of u s. Bcyc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide bicycle technology today announced progress updates across its wholly owned and partnered programs in oncology and non oncology indications. View all news news. 7 2020 bicycle therapeutics plc nasdaq.

Press release return to press releases. This constraint is designed to confer high affinity and selectivity and the relatively large. 2 2020 bicycle therapeutics plc nasdaq. Cambridge u k and boston mass february 20 2019 bicycle therapeutics a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide bicycle product platform today announced several key changes to its executive team including the appointment of peter b.

Bcyc a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide bicycle technology today announced that the first patient has been dosed in the phase iia expansion portion of the phase i iia trial sponsored by cancer research uk the world s leading cancer charity dedicated to saving lives through research. Cambridge england boston business wire apr. September 3 2020 bicycle therapeutics to participate in upcoming virtual investor conferences. Cambridge england boston business wire sep.